Search This Blog

Wednesday, November 30, 2022

BioNTech, Ryvu in Collaboration for Immuno-Modulatory Small Molecule Candidates

 

  • The companies enter a multi-target research collaboration to develop multiple small molecule programs targeting immune modulation in cancer and potentially other disease areas based on targets selected by BioNTech

  • In addition to these programs, BioNTech will receive a global, exclusive license to develop and commercialize Ryvu’s STING agonist portfolio as standalone small molecules

  • Ryvu will receive €40 million from BioNTech, comprised of a €20 million upfront payment and an equity investment of €20 million, as well as research funding. Additionally, Ryvu is eligible to receive R&D and commercial milestone payments in addition to low single-digit royalties

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.